Results 101 to 110 of about 114,024 (159)

Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events. [PDF]

CPT Pharmacometrics Syst Pharmacol
Yassen A, Kanefendt F, Zisowsky J, Broeker A, Mundl H, Vis P, Garmann D, Berkhout J.   +7 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors. [PDF]

CPT Pharmacometrics Syst Pharmacol
Babel H, Brunsdon P, Engelhardt B, Schmitt V, Ratajczak C, Mensing S, Menon RM, Parikh A.   +7 more
europepmc   +1 more source

Population Pharmacokinetics and Model-Informed Dose Optimization of Teicoplanin in Adults with Hematological Malignancies. [PDF]

Pharmaceutics
García-Hervalejo M, Sánchez-Hernández JG, Conde-González I, Avendaño Pita A, Otero MJ.   +4 more
europepmc   +1 more source

Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects. [PDF]

Front Pharmacol
He Y, Hu J, Zeng X, Yang Q, You Q, Huang J, Zhang Y, Si L, Zhai X.   +8 more
europepmc   +1 more source

Population pharmacokinetics of tenofovir alafenamide delivered via an annual subdermal implant in South African women. [PDF]

Sci Rep
Beliveau M, Chang C, Lewis L, Letsoalo MP, Karim QA, Karim SSA, Marzinke MA, Moss JA, Gengiah TN, Baum MM.   +9 more
europepmc   +1 more source

Population pharmacokinetics of fosmidomycin and clindamycin in combination with artesunate for uncomplicated Plasmodium falciparum malaria in Gabonese children and adults. [PDF]

Malar J
Pfaffendorf C, Dejon-Agobé JC, Edoa JR, Maïga-Ascofaré O, Ahenkan E, Adegnika AA, Ramharter M, Wicha SG, Mischlinger J.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Population Pharmacokinetics of Lamotrigine

Therapeutic Drug Monitoring, 2001
The present study estimated the population pharmacokinetics of lamotrigine in patients receiving oral lamotrigine therapy with drug concentration monitoring, and determined intersubject and intrasubject variability. A total of 129 patients were analyzed from two clinical sites. Of these, 124 patients provided sparse data (198 concentration-time points);
Chan, V., Morris, R., Ilet, K., Tett, S.
openaire   +5 more sources

Population Pharmacokinetics

Clinical Pharmacokinetics, 1999
The application of population approaches to drug development is recommended in several US Food and Drug Administration (FDA) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge upon drug safety and efficacy.
H, Sun, E O, Fadiran, C D, Jones, L, Lesko, S M, Huang, K, Higgins, C, Hu, S, Machado, S, Maldonado, R, Williams, M, Hossain, E I, Ette   +11 more
openaire   +2 more sources

Population pharmacokinetics of oxaliplatin

Cancer Chemotherapy and Pharmacology, 2002
The objective of this study was to explore correlations between a variety of covariates and oxaliplatin ultrafilterable and blood pharmacokinetic parameters. Data from 40 patients receiving oxaliplatin combined with 5-fluorouracil and levofolinic acid as standard treatment for advanced colorectal cancer were analysed. Plasma ultrafilterable, blood, and
Jean-Pierre, Delord, Amine, Umlil, Rosine, Guimbaud, Nicolas, Grégoire, Thierry, Lafont, Pierre, Canal, Roland, Bugat, Etienne, Chatelut   +7 more
openaire   +2 more sources